evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

12 questions · 12 findings · 4 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 16.7%Low 9 · 75%Moderate 1 · 8.3%High 0 · 0%

Paracetamol vs placebo

Withdrawals due to adverse events · Patients with osteoarthritis of the knee or hip

Paracetamol showed no clear difference in withdrawals due to adverse events 24 weeks compared with placebo (moderate certainty).

1 finding from 1 review

Cromolyn sodium vs placebo

Withdrawals due to adverse events · active EoE pediatric patients

Cromolyn sodium showed no clear difference in withdrawals due to adverse events at 8 weeks compared with placebo (low certainty).

1 finding from 1 review

Viaskin milk patch vs placebo

Withdrawals due to adverse events · active EoE pediatric patients

Viaskin milk patch showed no clear difference in withdrawals due to adverse events at 44 weeks compared with placebo (low certainty).

1 finding from 1 review

Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab

Withdrawals due to adverse outcomes · Participants with active Crohn's disease despite current treatment with infliximab

Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in withdrawal due to adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).

1 finding from 1 review

Corticosteroids vs placebo

Withdrawals due to adverse events · inactive EoE patients

Corticosteroids may leads to lower withdrawals due to adverse events 12 to 50 weeks compared with placebo (low certainty).

1 finding from 1 review

Biologics vs placebo

Withdrawals due to adverse events · active EoE patients

Biologics showed no clear difference in withdrawals due to adverse events 12 to 44 weeks compared with placebo (low certainty).

1 finding from 1 review

Infliximab vs placebo

Withdrawals due to adverse events · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)

It is very uncertain whether infliximab changes withdrawal due to adverse events (at 32‐54 weeks) compared with placebo (very low certainty).

1 finding from 1 review

Corticosteroids vs placebo

Withdrawals due to adverse events · active EoE patients

Corticosteroids may leads to lower withdrawals due to adverse events (2 to 12 weeks) compared with placebo (low certainty).

1 finding from 1 review